Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock

Deciphera Pharmaceuticals (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has commenced a proposed public offering of 3,750,000 in shares of its common stock. In addition, Deciphera also intends to grant the underwriters a 30-day option to purchase up to 562,500 shares of its common stock.

As quoted in the press release:

A registration statement relating to the offering has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.

The offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, by email at prospectus-eq_fi@jpmchase.com or by telephone at (866) 803-9204, or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at emailprospectus@pjc.com.

Click here to read the full press release.